fulvestrant has been researched along with Metastase in 105 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.90) | 18.2507 |
| 2000's | 15 (14.29) | 29.6817 |
| 2010's | 71 (67.62) | 24.3611 |
| 2020's | 17 (16.19) | 2.80 |
| Authors | Studies |
|---|---|
| Artham, S; Bae, Y; Baldi, R; Brueckner, O; Byemerwa, J; Chakraborty, B; Chang, CY; Gong, W; Haines, CN; Hanks, BA; Lim, F; Liu, W; McDonnell, DP; Mukherjee, D; Perou, CM; Shepherd, J; Tavares, K; Wardell, SE | 1 |
| Amiri-Kordestani, L; Beaver, JA; Bloomquist, E; Cheng, J; Gao, JJ; Ison, G; Krol, D; Osgood, C; Pazdur, R; Prowell, TM; Royce, M; Sridhara, R; Tang, S; Wedam, SB | 1 |
| Cheng, MY; Gao, HF; Ji, F; Li, JQ; Niu, G; Wang, K; Yang, CQ; Yang, M; Zhang, JS; Zhang, LL; Zhang, QZ; Zhu, T | 1 |
| Raj, GV; Soleja, M; Unni, N | 1 |
| Agarwal, S; Chang, DW | 1 |
| Rugo, HS | 1 |
| Bun, A; Fujimoto, Y; Fukui, R; Higuchi, T; Imamura, M; Miyagawa, Y; Miyoshi, Y; Ozawa, H; Sata, A | 1 |
| Hua, YM | 1 |
| Exinger, D; Fischbach, C; Herrscher, H; Kalish-Weindling, M; Leblanc, J; Petit, T; Pivot, X; Velten, M | 1 |
| Alchami, F; Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; Cox, C; Foxley, A; Howell, SJ; Joffe, J; Jones, RH; Madden, TA; Moon, S; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Buisseret, L; de Azambuja, E; Eiger, D; Nogueira, MS; Pondé, NF; Wagner, M | 1 |
| Di, G; He, M; Liu, C; Liu, G; Liu, Y; Shao, Z; Shi, Q; Sun, Y; Wang, Z; Xu, X; Yang, Z; Yuan, H; Zhang, Y | 1 |
| Ai, B; Cao, X; Fan, S; Li, D; Li, L; Liao, Y; Qiu, W | 1 |
| Cao, WM; Chen, JQ; Chen, ZH; Huang, J; Huang, P; Huang, Y; Lei, L; Lou, CJ; Shao, XY; Sun, Y; Wang, XJ; Ye, WW; Zheng, YB | 1 |
| Bergqvist, M; Bethune, A; Bidard, FC; Brain, E; Cabel, L; Cottu, P; Donnadieu, A; Kiavue, N; Lerebours, F; Loirat, D; Pierga, JY; Rodrigues, M; Rosenblum, D; Tanguy, ML | 1 |
| Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Chatterjee, DK; Chen, W; Chen, X; Fan, J; Fernandes, LL; Gao, JJ; Geiser, G; Ghosh, S; Goldberg, KB; Gong, Y; Jiang, X; King-Kallimanis, BL; Kluetz, PG; Li, E; Narayan, P; Pathak, A; Pazdur, R; Philip, R; Prowell, TM; Qiu, J; Reyes Turcu, F; Rhieu, SY; Ricks, TK; Seidman, J; Song, P; Tang, S; Theoret, MR; Wang, X; Windsor, K; Yu, J; Zhang, X | 1 |
| Bernard-Tessier, A; Bidard, FC; Bièche, I; Cabel, L; Cottu, P; Darrigues, L; Dubot, C; Geiss, R; Loirat, D; Michel, M; Pierga, JY; Proudhon, C; Ricci, F; Silveira, AB; Vincent-Salomon, A | 1 |
| Isaacs, C; O'Regan, R; O'Shaughnessy, JA | 1 |
| Chang, YF; Fanning, SW; Green, B; Greene, GL; Greene, ME; Komm, B; Kurleto, JD; Lainé, M; Phung, L | 1 |
| Jeselsohn, RM | 1 |
| Alba, E; Alvarez, E; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, M; Ciruelos, E; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Gil-Gil, M; González-Santiago, S; Kahan, Z; Lang, I; López, IÁ; Margeli, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Rodrigálvarez, G; Rodríguez, CA; Ruiz-Borrego, M; Servitja, S; Zielinski, C | 1 |
| Brown, M; De Angelis, C; Jeselsohn, R; Schiff, R | 1 |
| Kim, ES; Scott, LJ | 1 |
| Arteaga, CL; Awada, A; Baselga, J; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; Dharan, B; Di Tomaso, E; Hachemi, S; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Massacesi, C; Masuda, N; Pistilli, B; Takahashi, M; Tseng, LM; Urban, P; Vuylsteke, P | 1 |
| Adjei, AA; Ames, MM; Black, J; Buhrow, SA; Chalmers, ZR; Collins, JM; Dockter, T; Doroshow, JH; Erlichman, C; Frampton, G; Goetz, MP; Haddad, T; Hawse, JR; Ingle, JN; Kipp, BR; Kuffel, M; Liu, MC; Mahr, MA; McGovern, RM; Northfelt, DW; Ralya, AT; Reid, JM; Safgren, SL; Streicher, H; Suman, VJ; Visscher, D | 1 |
| Abenhardt, W; Beckmann, MW; Belleville, E; Brucker, SY; Ettl, J; Fasching, PA; Fehm, TN; Fersis, N; Geberth, M; Häberle, L; Hadji, P; Hartkopf, AD; Hielscher, C; Huober, J; Janni, W; Kolberg, HC; Kurbacher, C; Lüftner, D; Lux, MP; Müller, V; Nabieva, N; Overkamp, F; Schneeweiss, A; Schwitulla, J; Taran, FA; Tesch, H; Thomssen, C; Untch, M; Volz, B; Wallwiener, D; Wallwiener, M; Wimberger, P; Wuerstlein, R | 1 |
| Kim, ES | 1 |
| D'Assoro, A; Goetz, MP; Haddad, TC; Ingle, JN; Liu, MC; Opyrchal, M; Peethambaram, P; Suman, V | 1 |
| Ciccarese, M; Cinieri, S; Fedele, P; Surico, G | 1 |
| Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, A; Diéras, V; Ettl, J; Finn, RS; Gelmon, KA; Giorgetti, C; Im, SA; Iyer, S; Lipatov, O; Lu, DR; Martin, M; Mori, A; Moulder, S; Turner, NC | 1 |
| Akiyoshi, S; Ijichi, H; Ishida, M; Koga, C; Koi, Y; Masuda, T; Nakamura, Y; Ohno, S; Tokunaga, E | 1 |
| Ahn, JS; Heo, MH; Im, YH; Kim, HK; Kim, JY; Lee, H; Park, YH | 1 |
| Lindman, H; Valachis, A; Zewenghiel, L | 1 |
| Alves, CL; Bak, M; Ditzel, HJ; Elias, D; Lyng, MB | 1 |
| Iguchi, E; Kawamura, Y; Kawasaki, S; Morita, M; Nakatsukasa, K; Nishida, M; Oouchi, Y; Sakaguchi, K; Sakuramachi, A; Soshi, M; Taguchi, T; Watanebe, A | 1 |
| Adams, B; Brennan, M; Dacic, S; Davenport, S; Dubinett, SM; Elashoff, D; Elashoff, RM; Garon, EB; Grogan, T; Hu, EH; Marquez-Garban, DC; Parikh, RJ; Park, DJ; Patel, R; Pietras, RJ; Press, MF; Reckamp, KL; Sadeghi, S; Siegfried, JM; Slamon, DJ; Stabile, LP; Valdes, Y; Wang, HJ; Young, PA | 1 |
| Augereau, P; Campone, M; Chassain, K; Guillemois, S; Le Corre, Y; Patsouris, A; Peyraga, G | 1 |
| Acconcia, F; Bianchi, F; Busonero, C; Leone, S | 1 |
| Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J | 1 |
| Gong, C; Li, Y; Liu, C; Wang, B; Wu, B; Xie, Y; Yang, Z; Zhang, Y; Zhao, Y | 1 |
| Agrapart, V; Andre, F; Bachelot, T; Bossard, CJ; Campone, M; Dubois, F; Guigal-Stephan, N; Lockhart, B; Pallis, A; Penault-Llorca, F; Pierrat, MJ; Poirot, C; Xuereb, L | 1 |
| Chen, Z; Gong, C; Hu, S; Hu, X; Li, Y; Wang, B; Wang, L; Xie, Y; Yuan, P; Zhang, J; Zhang, Y; Zhao, Y | 1 |
| André, F; Arnedos, M; Bayar, MA; Colleoni, M; Cristofanilli, M; DeMichele, A; Giorgetti, C; Harbeck, N; Huang Bartlett, C; Liu, Y; Loi, S; Loibl, S; Michiels, S; Turner, NC; Zhang, Z; Zhu, Z | 1 |
| Cao, E; Ge, R; Gong, C; Guan, X; Hu, X; Li, W; Li, Y; Wang, B; Wang, L; Xie, Y; Zhang, J; Zhang, S; Zhang, Y; Zhao, Y | 1 |
| Abraham, J; Budd, GT; Eziokwu, AS; Jia, X; Kruse, M; Montero, AJ; Moore, HCF; Varella, L | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Linden, HH; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA | 1 |
| Burki, TK | 1 |
| Benelli, M; Bergqvist, M; Biagioni, C; Biganzoli, L; Boccalini, G; Bonechi, M; Chia, S; De Luca, F; Di Leo, A; Galardi, F; Gradishar, WJ; Malorni, L; Mattsson, K; McCartney, A; Migliaccio, I; Pestrin, M; Piccart, M; Romagnoli, D; Schiavon, G | 1 |
| Guan, X; Li, C; Li, L; Liu, B; Ma, F; Qian, H; Xu, B; Yi, Z | 1 |
| Clarke, RB; Dragoni, I; Gee, JM; Howell, SJ; Kedward, T; NicAmhlaoibh, R; Sabin, V; Santiago-Gómez, A; Simões, BM; Sims, AH; Trivier, E | 1 |
| Balatti, V; Byrd, JC; Cascione, L; Consiglio, J; Coppola, V; Croce, CM; De Luca, L; Freitas, MA; Gasparini, P; Guan, J; Hofmeister, CC; Lagana, A; Marcucci, G; Nuovo, G; Palmieri, D; Pichiorri, F; Piovan, C; Rocci, A; Shapiro, CL; Talabere, T; Volinia, S; You, J | 1 |
| Anderson, D; Dueck, AC; Flynn, P; Northfelt, D; Perez, EA; Rowland, K; Steen, P; Tan, WW | 1 |
| Alencar, VM; Audeh, MW; Brown, K; Chan, A; de Oliveira, C; Hyams, DM; Klein, P; Lombard, J; Mookerjee, B; Snyder, R; Vinholes, J; Xu, J | 1 |
| Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D | 1 |
| Helgason, CD; Mager, DL; Nakamura, H; Romanish, MT; Wang, Y; Xue, H | 1 |
| Blakely, LJ; Houts, AC; Schwartzberg, LS; Somer, BG; Stepanski, EJ; Walker, MS; Wang, G; Wheeler, BM | 1 |
| Fujita, T; Gondo, N; Hattori, M; Horio, A; Ichikawa, M; Idota, A; Iwata, H; Kondo, N; Sawaki, M; Ushio, A | 1 |
| Al-Qaisi, A; Awasthi, M; Chen, A; Chen, L; Kadamyan-Melkumyan, V; Massarweh, S; Romond, E | 1 |
| Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ | 1 |
| Brown, M; de Vries, EF; de Vries, EG; Glaudemans, AW; Hospers, GA; Kema, IP; Schröder, CP; van Faassen, M; van Kruchten, M; van Lanschot, MC | 1 |
| Iwase, H; Yamamoto, Y | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Adachi, K; Amano, S; Enomoto, K; Fujisaki, S; Gonda, K; Masuo, Y; Matsuo, S; Nagashima, S; Sakurai, K; Suzuki, S; Tomita, R; Umeda, N | 1 |
| Ademuyiwa, F; Ellis, MJ; Griffith, M; Griffith, OL; Guo, Z; Han, J; Hoog, J; Lockhart, C; Luo, J; Ma, CX; Mardis, E; Nagaraj, G; Naughton, M; Pluard, T; Ramu, A; Skidmore, ZL; Spies, NC; Suresh, R; Thomas, S; Trani, L | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Bartlett, CH; Bondarenko, I; Colleoni, M; Cristofanilli, M; DeMichele, A; Harbeck, N; Im, SA; Iwata, H; Jiang, Y; Koehler, M; Loi, S; Masuda, N; Ro, J; Slamon, D; Theall, KP; Turner, NC; Verma, S; Zhang, K | 1 |
| Gorska, M; Kuban-Jankowska, A; Wozniak, M; Wyszkowska, RM | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Festinese, F; Galli, G; Ganzinelli, M; Gevorgyan, A; Lo Vullo, S; Mariani, L; Martinetti, A; Sottotetti, E | 1 |
| Nakai, M; Takei, H; Uchida, E; Yamashita, K; Yanagihara, K | 1 |
| Currin, ER; Krohn, KA; Kurland, BF; Lee, JH; Linden, HM; Link, JM; Mankoff, DA; Peterson, LM; Schubert, EK | 1 |
| Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, AM; Harbeck, N; Iwata, H; Loi, S; Ro, J; Rugo, HS; Schnell, P; Thiele, A; Turner, NC; Verma, S; Zhang, K | 1 |
| Blondeaux, E; Del Mastro, L; Lambertini, M; Levaggi, A; Poggio, F; Pronzato, P; Vaglica, M | 1 |
| Adachi, K; Enomoto, K; Fujisaki, S; Gonda, K; Hara, Y; Hirano, T; Masuo, Y; Nagashima, S; Sakurai, K; Suzuki, S; Tomita, R | 1 |
| Adhikari, VP; Dai, W; Kong, LQ; Li, X; Luo, QQ; Wu, H; Wu, KN; Wu, YT; Zhao, CX | 1 |
| Berger, K; Gligorov, J; Lewis, J; Maass, N; MacDougall, F; Marchetti, P; Montonen, J | 1 |
| André, F; Barrios, CH; Blackwell, K; Bonnefoi, H; Campone, M; Cortes, J; Denduluri, N; Deudon, S; Kahan, Z; Musolino, A; Neven, P; Shi, MM; Soliman, H; Squires, M; Zhang, Y | 1 |
| Ben-Yosef, R; Greenberg, J; Inbar, M; Ron, IG; Safra, T; Sarid, D; Yaal-Hahoshen, N | 1 |
| Flemming, J; Franek, JA; Madarnas, Y | 1 |
| Cheung, KL; Rampaul, RS; Tang, JY | 1 |
| Christos, PJ; Hershman, DL; Hoschander, S; Li, T; O'Brien, K; Sparano, JA; Vahdat, LT; Wright, JJ | 1 |
| Alonso Muñoz, A; García Alfonso, P; Martínez Marín, V; Muñoz Martín, AJ; Pérez Manga, G; Viñuela Benéitez, MC | 1 |
| Ahmad, I; Amir, E; Chia, S; Clemons, M; Dent, S; Dranitsaris, G; Fralick, M; Freedman, O; Kumar, R; Napolskikh, J; Petrella, T; Rayson, D; Tonkin, K | 1 |
| Borges, VF; Kabos, P | 1 |
| Bonebrake, A; Covens, AL; Filiaci, V; Gersell, D; Lee, YC; Lutman, CV | 1 |
| Beckman, BS; Bratton, MR; Burow, ME; Collins-Burow, BM; Curiel, TJ; Dent, P; Elliott, S; Fonseca, JP; Fuqua, SA; Horton, LW; Hung, MC; Muir, SE; Neel, NF; Nephew, KP; Rhodes, LV; Richmond, A; Salvo, VA; Segar, C; Short, SP; Sobolik-Delmaire, T; Sun, M; Tilghman, SL; Wadsworth, S; Wei, Y; Wood, CE; Worthylake, RA; Yu, D; Zaja-Milatovic, S; Zhu, Y | 1 |
| Hayes, E; Hiscox, S; Nicholson, RI | 1 |
| Arrowsmith, E; Barton, J; Burris, HA; Clark, BL; Hainsworth, JD; Rubin, M; Shipley, D; Yardley, DA | 1 |
| Ellis, GK; Gralow, JR; Krohn, KA; Kurland, BF; Lawton, TJ; Linden, HM; Link, JM; Livingston, RB; Mankoff, DA; Peterson, LM; Petra, PH; Schubert, EK; Specht, JM | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| Litsas, G | 1 |
| Badve, SS; Carlson, RW; Gomez, HL; O'Neill, A; Sledge, GW; Vidaurre, T | 1 |
| Bago-Horvath, Z; Bartsch, R; Berghoff, A; DeVries, C; Dubsky, P; Fitzal, F; Gnant, M; Mader, RM; Pluschnig, U; Rottenfusser, A; Rudas, M; Steger, GG; Zielinski, CC | 1 |
| Aapro, M; Bischoff, J; Brain, E; Cardoso, F; Lück, HJ; Tanner, M; Tjan-Heijnen, VC; Zotano, ÁG | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA | 1 |
| Burton, G; Buzdar, A; Come, S; Dimery, I; Elledge, R; Ellis, M; Gertler, SZ; Jones, SE; May, JT; Morris, C; Osborne, CK; Parker, LM; Pippen, J; Webster, A | 1 |
| Aschermannova, A; Erikstein, B; Howell, A; Kleeberg, UR; Mauriac, L; Morris, C; Quaresma Albano, J; Robertson, JF; Vergote, I; Webster, A | 1 |
| Curran, MP; McKeage, K; Plosker, GL | 1 |
| Franco, S; Frankel, C; Perez, A; Tan-Chiu, E; Vogel, CL | 1 |
| McDonald, D; Morrissey, C; O'Sullivan, J; Schneider, MR; Tenniswood, MP; Vollmer, G; Wünsche, W; Zierau, O | 1 |
| Ponzone, R; Sismondi, P | 1 |
| Gorbunova, VA; Howell, A; Lichinitser, MR; Pienkowski, T; Robertson, JF; Watanabe, T | 1 |
| Greil, R; Hauser-Kronberger, C; Mayer, P; Mlineritsch, B; Moik, M; Namberger, K; Psenak, O | 1 |
| Awada, A; Azerad, MA; Becquart, D; Bols, A; Borms, M; Christiaens, MR; Cocquyt, V; De Greve, J; Demol, J; Dirix, L; Fontaine, C; Goeminne, JC; Martens, M; Neven, P; Paridaens, R; Pelgrims, G; Selleslags, J; Stragier, B; Van Dam, P; Van Den Broecke, R; Van Den Weyngaert, D; Vandenhoven, G; Vergote, I; Vindevoghel, A | 1 |
| DePasquale, JA | 1 |
| Pento, JT; Rajah, TT | 1 |
17 review(s) available for fulvestrant and Metastase
| Article | Year |
|---|---|
An evaluation of fulvestrant for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Metastasis | 2019 |
Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer.
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Mutation; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2 | 2019 |
An evidence-based review of the outcome of fulvestrant plus a targeted agent versus fulvestrant alone in treating hormone receptor-positive endocrine therapy-resistant metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2019 |
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
Topics: Alopecia; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Fulvestrant; Germany; Humans; Incidence; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Survival Rate; Tamoxifen | 2020 |
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mutation; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prognosis; Tamoxifen | 2017 |
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Triazoles | 2017 |
Abemaciclib: First Global Approval.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinases; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; United States; United States Food and Drug Administration | 2017 |
An update on first line therapies for metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Immunotherapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Steroid | 2018 |
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2014 |
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone Acetate; Neoplasm Metastasis; Ovariectomy; Postmenopause; Premenopause; Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Postmenopause; Treatment Outcome | 2016 |
Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Postmenopause | 2009 |
Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Delivery Systems; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2010 |
Acquired endocrine resistance in breast cancer: implications for tumour metastasis.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Hyaluronan Receptors; Neoplasm Metastasis; Proto-Oncogene Proteins c-met; src-Family Kinases | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Tamoxifen | 2013 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
34 trial(s) available for fulvestrant and Metastase
| Article | Year |
|---|---|
A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; Receptor, ErbB-2; Receptors, Cell Surface; Retrospective Studies | 2019 |
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Pyrroles; Receptors, Estrogen; Salvage Therapy; Survival Rate | 2020 |
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Drug Approval; Female; Fulvestrant; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Patient Reported Outcome Measures; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles | 2021 |
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Health Status; Humans; Israel; Neoplasm Metastasis; Patient Reported Outcome Measures; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality of Life; Time Factors | 2021 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Eruptions; Estradiol; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Retreatment; Signal Transduction; Survival Rate | 2017 |
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Aromatase Inhibitors; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cytochrome P-450 CYP2D6; Disease-Free Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Tamoxifen | 2017 |
Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Azepines; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Pyrimidines | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Progression-Free Survival; Pyridines; Quality of Life; Viscera | 2018 |
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fulvestrant; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2018 |
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Goserelin; Humans; Neoplasm Metastasis; Premenopause; Tamoxifen | 2018 |
Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study.
Topics: Adult; Aged; Breast Neoplasms; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Survival Rate | 2018 |
A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Fulvestrant; Humans; Maximum Tolerated Dose; Middle Aged; Naphthalenes; Neoplasm Metastasis; Postmenopause; Quinolines; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Estrogen | 2019 |
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin E; Female; Fulvestrant; Gene Expression Profiling; Humans; Neoplasm Metastasis; Oncogene Proteins; Piperazines; Progression-Free Survival; Proportional Hazards Models; Pyridines; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger | 2019 |
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Estrogen Receptor Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Postmenopause; Progression-Free Survival | 2019 |
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Metastasis; Prognosis; Thymidine Kinase | 2019 |
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Receptors, Estrogen; Vascular Endothelial Growth Factor A | 2013 |
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factor 2; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Estradiol; Female; Fluorouracil; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2014 |
Everolimus-induced hematologic changes in patients with metastatic breast cancer.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Erythrocyte Count; Erythrocyte Indices; Estradiol; Everolimus; Female; Fulvestrant; Hematologic Diseases; Humans; Leukocyte Count; Leukopenia; Neoplasm Metastasis; Sirolimus; Thrombocytopenia | 2015 |
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phas
Topics: Adult; Aged; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Piperazines; Pyridines; Receptor, ErbB-2; Treatment Outcome | 2016 |
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2016 |
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Survival Analysis; Treatment Outcome | 2017 |
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Farnesyltranstransferase; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Quinolones; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2009 |
Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease-Free Survival; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptors, Estrogen; Receptors, Progesterone | 2011 |
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2011 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles | 2012 |
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Goserelin; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Premenopause | 2012 |
Combination anastrozole and fulvestrant in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2012 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; North America; Postmenopause; Quality of Life; Survival Rate; Triazoles | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Logistic Models; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quality of Life; Survival Rate; Triazoles | 2002 |
Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Metastasis; Postmenopause; Treatment Outcome | 2004 |
Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Empathy; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Palliative Care; Program Evaluation; Prospective Studies; Quality of Life; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome | 2007 |
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Belgium; Breast Neoplasms; Endocrine System; Estradiol; Estrogens; Female; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2008 |
54 other study(ies) available for fulvestrant and Metastase
| Article | Year |
|---|---|
Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Immune System; Macrophages; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Myeloid Cells; Neoplasm Metastasis; Receptors, Estrogen; RNA, Small Cytoplasmic; Signal Transduction; Skin Neoplasms; Tumor Microenvironment | 2021 |
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Progesterone; Survival Rate; United States; United States Food and Drug Administration | 2021 |
Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fatal Outcome; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Peritoneal Neoplasms | 2021 |
Breast reconstruction in the patient with stable, metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Life Expectancy; Mammaplasty; Mastectomy; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyridines; Quality of Life | 2020 |
Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyridines; Retreatment; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
The Predictive Value of Early Changes in
Topics: Breast Neoplasms; Female; Fluorodeoxyglucose F18; Fulvestrant; Humans; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Receptors, Estrogen | 2020 |
Targeting Toll-like receptor 4 with CLI-095 (TAK-242) enhances the antimetastatic effect of the estrogen receptor antagonist fulvestrant on non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Movement; Estrogen Receptor Antagonists; Estrogen Receptor beta; Female; Fulvestrant; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Sulfonamides; Toll-Like Receptor 4 | 2020 |
Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series.
Topics: Adult; Antineoplastic Agents, Hormonal; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Progression-Free Survival; Retrospective Studies; Safety; Time-to-Treatment; Treatment Outcome | 2020 |
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Prospective Studies; Pyridines; Receptor, ErbB-2; Survival Rate; Tamoxifen; Thymidine Kinase | 2020 |
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyridines; Survival Analysis; Treatment Outcome | 2021 |
Neratinib: an option for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Disease Management; Female; Fulvestrant; Humans; Neoplasm Metastasis; Oxazoles; Pyridines; Quality of Life; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Estrogen Receptor alpha; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mutation; Neoplasm Metastasis; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome | 2021 |
The evolving use of SERDs in estrogen receptor-positive, HER2-negative metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Indoles; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2021 |
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Germany; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen | 2018 |
Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptors, Steroid; Treatment Outcome; Viscera | 2018 |
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Electronic Health Records; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salvage Therapy; Time Factors | 2019 |
Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer - A retrospective two-center cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Obesity; Overweight; Postmenopause; Retrospective Studies; Sweden; Treatment Outcome | 2018 |
SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Middle Aged; Neoplasm Metastasis; Snail Family Transcription Factors | 2018 |
[Experience of Fulvestrant for Hormone Receptor-Positive HER2-Negative Advanced and Metastatic Breast Cancer].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2018 |
Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report.
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fulvestrant; Gastroenteritis; Humans; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyridines; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2018 |
In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Computer Simulation; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mitoxantrone; Neoplasm Metastasis; Reproducibility of Results; Tamoxifen; Thioridazine | 2018 |
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Capecitabine; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2019 |
Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Pyridines; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Fulvestrant plus anastrozole for metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Everolimus; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Patient Selection; Precision Medicine; Receptors, Steroid; Retrospective Studies; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome | 2019 |
PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression; Humans; MCF-7 Cells; Meta-Analysis as Topic; Neoplasm Metastasis; Neoplastic Stem Cells; p21-Activated Kinases; Prognosis; Receptors, Estrogen; Small Molecule Libraries; Tamoxifen | 2019 |
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
Topics: Animals; Aptamers, Nucleotide; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Genes, Neoplasm; Guanine; HEK293 Cells; Humans; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleolin; Oligodeoxyribonucleotides; Phosphoproteins; RNA-Binding Proteins; Transcription, Genetic; Up-Regulation | 2013 |
Genistein versus ICI 182, 780: an ally or enemy in metastatic progression of prostate cancer.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Disease Progression; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Genistein; Humans; Male; Metallothionein; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Prostatic Neoplasms; RNA, Small Interfering; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
[Assessment of the clinical efficacy and safety of fulvestrant in heavily pretreated patients with hormone-receptor positive metastatic breast cancer-a single-institution experience].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; Recurrence | 2013 |
Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Receptors, Estrogen; Tamoxifen; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
[Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor-Resistant Metastatic Breast Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Middle Aged; Neoplasm Metastasis; Recurrence | 2015 |
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Postmenopause; PTEN Phosphohydrolase; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Impact of Apparent Antagonism of Estrogen Receptor β by Fulvestrant on Anticancer Activity of 2-Methoxyestradiol.
Topics: 2-Methoxyestradiol; Antineoplastic Agents, Hormonal; Apoptosis; Bone Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Histones; Humans; Neoplasm Metastasis; Neoplasm Proteins; Osteosarcoma; Phosphorylation; Protein Processing, Post-Translational | 2016 |
Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Obesity; Postmenopause; Receptors, Estrogen; Risk Factors; Treatment Outcome | 2016 |
Combining Fulvestrant with Low-Dose Capecitabine is Effective and Tolerable in Woman with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Breast Neoplasms, Male; Disease-Free Survival; Estradiol; Estrogen Receptor alpha; Female; Fluorodeoxyglucose F18; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2 | 2017 |
[Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Multiple Metastatic Breast Cancer Patients].
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Neoplasm Metastasis; Recurrence | 2016 |
Chemosensitization role of fulvestrant in combination with chemotherapy in postmenopausal hormone receptor positive and human epidermal growth factor negative metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Hormones; Humans; Neoplasm Metastasis; Postmenopause; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2016 |
Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Databases, Factual; Drug Prescriptions; Estradiol; Female; France; Fulvestrant; Germany; Humans; Italy; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome | 2017 |
Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Estradiol; Female; Fulvestrant; Humans; Intestinal Obstruction; Middle Aged; Neoplasm Metastasis | 2008 |
[Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Estradiol; Estrogen Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Retrospective Studies; Time Factors; Treatment Outcome | 2009 |
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Area Under Curve; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Models, Statistical; Neoplasm Metastasis; Palliative Care; Risk Assessment; ROC Curve; Treatment Outcome; Young Adult | 2009 |
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Receptors, CXCR4; Receptors, Estrogen | 2011 |
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2011 |
Nursing perspectives on fulvestrant for the treatment of postmenopausal women with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Patient Education as Topic; Postmenopause | 2011 |
Tamoxifen exerts agonistic effects on clusterin and complement C3 gene expression in RUCA-I primary xenografts and metastases but not normal uterus.
Topics: Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Complement C3; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Neoplasm Metastasis; Rats; Rats, Inbred Strains; RNA, Messenger; Tamoxifen; Transplantation, Heterologous; Uterus | 2004 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Gonadal Steroid Hormones; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Postmenopause; Retrospective Studies; Salvage Therapy; Tamoxifen; Treatment Outcome | 2005 |
Rearrangement of the F-actin cytoskeleton in estradiol-treated MCF-7 breast carcinoma cells.
Topics: Actins; Breast Neoplasms; Cadherins; Cell Movement; Cytoskeleton; Estradiol; Estrogen Antagonists; Fluorescent Antibody Technique; Fulvestrant; Humans; Microscopy, Video; Neoplasm Invasiveness; Neoplasm Metastasis; Tumor Cells, Cultured | 1999 |
Influence of antiestrogens on the invasiveness and laminin attachment of breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Basement Membrane; Breast Neoplasms; Cell Adhesion; Collagen; Drug Combinations; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Laminin; Microscopy, Electron, Scanning; Microvilli; Neoplasm Invasiveness; Neoplasm Metastasis; Proteoglycans; Pseudopodia; Tamoxifen; Tumor Cells, Cultured | 1999 |